Develops drugs for eye and inflammatory diseases.
Jun 2026Revenue $15.5B/yrExpenses $11.7B/yr
Expected to fall below break-even Sep 2035
Figures by year
Is Regeneron Pharmaceuticals still profitable?
Yes. In the 12 months to Jun 2026, revenue was $15.5B and expenses $11.7B. Its expenses are growing faster than its revenue, and the trends are projected to cross in Sep 2035.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $14.3B | $10.8B | $3.58B |
| Dec 2024 | $14.2B | $10.2B | $3.99B |
| Dec 2023 | $13.1B | $9.07B | $4.05B |
| Dec 2022 | $12.2B | $7.43B | $4.74B |
| Dec 2021 | $16.1B | $7.12B | $8.95B |
| Dec 2020 | $8.50B | $4.92B | $3.58B |
| Dec 2019 | $6.56B | $4.35B | $2.21B |
| Dec 2018 | $5.15B | $2.61B | $2.53B |
| Dec 2017 | $5.87B | $3.79B | $2.08B |
| Dec 2016 | $4.86B | $3.53B | $1.33B |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.